Amgen cracks the undruggable code, earning the FDA’s nod for first-ever KRAS inhibitor

Among the most famous “undruggable” targets in oncology is mutated KRAS — a cell surface protein tied to a range of aggressive cancer types. Looking to overcome the industry’s years of failures, Amgen finally appeared to crack the code and raced its lead compound through clinical trials. Now, just three…

...

Click to view original post